Skip to main content

Table 1 Clinical data of the study sample

From: Evaluation of left atrial deformation to predict left atrial stasis in patients with non-valvular atrial fibrillation – a pilot-study

  Overall Group 1 Group 2 p
  (n = 82) (n = 16) (n = 66)
   LAAT or sludge No changes
Demographics
Age 68.1 ± 10.6 70.7 ± 8.0 67.4 ± 11.1 0.516
Female gender 34.1% (28) 25% (4) 36.4% (24) 0.390
Body Mass Index (Kg/m2) 28.3 ± 4.1 26.6 ± 2.8 28.7 ± 4.3 0.100
Clinical data
AF episode duration > 1 month 61.0% (50) 93.8% (15) 53.0% (35) 0.003
CHADS2 2.0 ± 1.1 2.3 ± 1.4 1.9 ± 1.1 0.418
CHA2DS2-VASc 3.2 ± 1.6 3.7 ± 1.6 3.1 ± 1.6 0.247
Congestive heart failure 43.9% (36) 50% (8) 42.4% (28) 0.584
Hypertension 80.5% (66) 93.8% (15) 77.3% (51) 0.136
Diabetes mellitus 18.3% (15) 31.3% (5) 15.2% (10) 0.135
Previous stroke or TIA 13.4% (11) 18.8% (3) 12.1% (8) 0.485
Vascular disease 15.9% (13) 25.0% (4) 13.6% (9) 0.264
Anti-thrombotic medication
Aspirin 22.8% (18) 37.5% (6) 19.0% (12) 0.116
Clopidogrel 12.7% (10) 25.0% (4) 9.5% (6) 0.096
Warfarin 29.1% (23) 37.5% (6) 27.0% (17) 0.408
INR in patients treated with warfarin 2.4 ± 1.0 2.8 ± 1.6 2.2 ± 0.6 0.394
Dabigatran or Rivaroxaban* 15.2% (12) 18.8% (3) 14.3% (9) 0.657
Enoxaparin 35.4% (29) 25.0% (4) 37.9% (25) 0.334
Enoxaparin dosage (mg/Kg bid) 0.9 ± 0.2 1.0 ± 0 0.9 ± 0.2 0.288
  1. Legend: LAAT – left atrial appendage thrombus; AF – atrial fibrillation; TIA – transient ischemic attack; INR – international normalized ratio.
  2. *All patients were treated with dabigatran 110 mg bid except for two: one patient with rivaroxaban 20 mg id and another one with dabigatran 150 mg bid in group 2.